Both treatments induced CFS gene transcription, which was further increased after FANCD2 depletion, indicating that CFS genes respond to mitochondrial or ER stress-dependent UPR activation and that FANCD2 dampens this response (Fig. 5a). The gene discussed is FANCD2; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.